Douglas Elliman enters its Q1 2026 earnings cycle in an unusual position: the stock has surged 31% over the past month to $2.09, short sellers are rebuilding positions at a measured pace, and options traders are among the most call-heavy they've been all year — even as the underlying financials just printed a miss.
The most striking shift this week is the collapse in put/call ratio. It has dropped to 0.14, well below its 20-day average of 0.19. That is close to the lowest reading of the past 52 weeks, which sits at 0.05. Call volumes are dominating the options market by a wide margin, reflecting the most bullish options tilt seen in over a year for this stock. The setup is unusual given what Q1 results actually showed — adjusted EPS came in at -$0.14, down from -$0.05 a year ago, and revenue fell to $214M from $253M. The gap between the options tone and the fundamental reality is the tension at the heart of the DOUG story right now.
Short positioning adds a layer of nuance. Short interest has crept higher over the past month, rising roughly 18% to 2.6% of the free float, with a modest uptick of about 4% on the week. Yet the borrow market tells a different story — cost to borrow remains trivially cheap at 0.54%, and availability is exceptionally loose at 968% of short interest, meaning shares are plentiful relative to what's already borrowed. With availability nowhere near constrained, there is no structural pressure on short sellers, and the ORTEX short score of 38 sits mid-range. This is not a short that has conviction behind it.
On the institutional side, two moves deserve attention. Michael Liebowitz — Chairman, President and CEO — added 1.25 million shares in a filing dated April 10, making him one of the largest individual holders with nearly 4.7% of the company. James Kirkland, the CFO, registered a similar directional move, adding 1 million shares in the same period. Against that backdrop, the December 2025 insider sell activity from both Liebowitz (-$474K at $2.41) and Kirkland (-$207K at $2.76) reads more like routine year-end trimming than a loss of conviction, especially given the subsequent open-market buying. The net institutional picture also includes steady incremental additions from BlackRock, Vanguard, and Columbia Management, the latter adding over one million shares as of March 31.
The broader corporate backdrop has also shifted. Douglas Elliman reached a $17.5M settlement of the Strougo derivative litigation in late April, removing a governance overhang that had weighed on the story for some time. A new President of National Brokerage, Lena Johnson, was named in the same week. These moves suggest management is positioning the company for stability ahead, even as the revenue trajectory remains pressured by a sluggish residential real estate market.
The Q1 miss — revenue down 15% year-on-year, EPS deteriorating — is the clear bear case, and the March earnings event (where the stock fell 27% in a single session on an earlier release) is still fresh. The next earnings call is confirmed for May 12. How management frames the revenue trajectory and any commentary on the US housing market will be the key read-through, with the options market indicating investors are more focused on upside catalysts than downside hedging.
See the live data behind this article on ORTEX.
Open DOUG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
